Meeting
2017 ASCO Annual Meeting
Phase 1 multicenter trial of CUDC-907 in children and young adults with relapsed or refractory solid tumors, CNS tumors, and lymphoma.
Authors
David Stephen Shulman
Dana-Farber Cancer Institute/Boston Children's Hospital, Boston, MA
David Stephen Shulman , Clay Gustafson , Kieuhoa Tran Vo , Elizabeth Fox , Jodi Ann Muscal , Jeffrey G. Supko , Andrew E. Place , Susan N. Chi , Suzanne Shusterman , Gina Hanna , Jane O'Brien , Suzanne Ezrre , Cecilia Carlowicz , Wendy B. London , Steven G. DuBois
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Pediatric Oncology
Track
Pediatric Oncology
Sub Track
Pediatric Solid Tumors
Clinical Trial Registration Number
NCT02909777
Citation
J Clin Oncol 35, 2017 (suppl; abstr TPS10576)
DOI
10.1200/JCO.2017.35.15_suppl.TPS10576
Abstract #
TPS10576
Poster Bd #
333a
Abstract Disclosures
Similar Posters
Poster
2018 ASCO Annual Meeting
Phase I multicenter trial of CUDC-907 in children and young adults with relapsed/refractory solid tumors, CNS tumors, and lymphomas.
First Author: David Stephen Shulman
Poster
2022 ASCO Annual Meeting
Phase 1 study of KT-333, a targeted protein degrader, in patients with relapsed or refractory lymphomas, large granular lymphocytic leukemia, and solid tumors.
First Author: Alexander Starodub
Poster
2019 ASCO-SITC Clinical Immuno-Oncology Symposium
A pilot study of pembrolizumab in combination with decitabine and hypofractionated index lesion radiation in pediatric and young adult patients with relapsed and refractory solid tumors or lymphoma.
First Author: Brian Turpin
Poster
2014 ASCO Annual Meeting
A phase I study of cabozantinib (XL184) in children and adolescents with recurrent or refractory solid tumors, including CNS tumors: A Children’s Oncology Group phase I consortium trial.
First Author: Meredith K. Chuk